2021Journal of the American Academy of DermatologyRequires access

26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5

Peter Lio, Jennifer Soung, Jennifer Cather, Marta Casillas, Yuxin Ding, Amy M. De Lozier, Yun-Fei Chen, Eric L. Simpson

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Eczema Area and Severity Index, Medicine, Dermatology Life Quality Index, Atopic dermatitis, Discontinuation, Placebo, Quality of life (healthcare), Dermatology

Related papers

Back to paper searchBrowse research topicsOriginal source
26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5 — Research Paper | ScholarLens